TIGIT and neoplasm: Zhang et al. demonstrated that a blocking antibody directed against TIGIT not only improved NK cell antitumor activity but also induced a potent NK cell-dependent tumor-specific T cell immunity, enhancing the efficiency of PD-L1 treatments.